Compare Marqeta Inc (MQ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Smith & Nephew plc — how do they compare? Marqeta Inc trades at $15.94 (market cap $1.69B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Smith & Nephew plc is far larger — about 6.9× Marqeta Inc's market cap, and Smith & Nephew plc pays a 2.85% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | SNN | |
|---|---|---|
Market Cap | $1.69B | $11.63B |
Sector | Technology | Health |
52-Week High | $23.88 | $38.53 |
52-Week Low | $15.04 | $27.80 |
Enterprise Value | $1.01B | $14.66B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $16.26, down 1.93% on the day, with a bearish technical signal and neutral oscillators. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to positive net income projected for 2026. Recent news highlights product expansions with Google and partnerships in stablecoin-backed cards and European markets, signaling growth initiatives.
The stock offers potential upside to the $19 consensus price target, supported by earnings momentum and strategic partnerships. Key risks include high valuation multiples, intense competition in fintech, and reliance on continued execution amid moderating growth expectations in the second half of 2026.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
